Dronabinol oral solution - INSYS Therapeutics

Drug Profile

Dronabinol oral solution - INSYS Therapeutics

Alternative Names: Syndros; Tetrahydrocannabinol oral solution - INSYS Therapeutics; THC oral solution - INSYS Therapeutics

Latest Information Update: 29 Mar 2017

Price : $50

At a glance

  • Originator INSYS Therapeutics, Inc
  • Class Antiemetics; Appetite stimulants; Cannabinoids; Muscle relaxants; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Registered Anorexia; Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 23 Mar 2017 Dronabinol oral solution has been classified as a Schedule II controlled substance by the US Drug Enforcement Agency
  • 05 Jul 2016 Registered for Anorexia in USA (PO)
  • 05 Jul 2016 Registered for Chemotherapy induced nausea and vomiting in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top